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Bradykinesia (slowness of movement) and other characteristic motor manifestations
of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine
(L-DOPA). Long-term L-DOPA treatment, however, is associated with complications such
as motor fluctuations and dyskinesia that severely impair the quality of life. It is unclear
whether the effect of L-DOPA on spontaneous motor activity and its dyskinesia-inducing
effect share a common mechanism. To investigate the possible connection between
these two effects, we analyzed the spontaneous locomotor activity of parkinsonian rats
before surgery (unilateral injection of 6-OHDA in the right medial forebrain bundle), before
treatment with L-DOPA, during L-DOPA treatment (the “ON” phase), and after the end
of L-DOPA treatment (the “OFF” phase). We correlated the severity of dyskinesia (AIM
scores) with locomotor responses in the ON/OFF phases of chronic L-DOPA treatment
at two different doses. We treated three groups of parkinsonian animals with chronic
injections of 8 mg/kg L-DOPA, 6 mg/kg L-DOPA, and saline solution and one group of
non-lesioned animals with 8 mg/kg L-DOPA. At the end of the experiment, tyrosine
hydroxylase (TH) immunoreactivity was analyzed in the striatum of all parkinsonian rats.
We found no correlation between the severity of dyskinesia and spontaneous locomotor
activity in the ON or OFF phase of L-DOPA treatment. The only observed correlation was
between the pathological rotation induced by L-DOPA at the highest dose and locomotor
activity in the ON phase of L-DOPA treatment. In addition, a L-DOPA withdrawal effect
was observed, with worse motor performance in the OFF phase than before the start of
L-DOPA treatment. These findings suggest that different neural mechanisms underlie the
effect of L-DOPA on spontaneous motor activity and its dyskinesia-inducing effect, with a
different dose-response relationship for each of these two effects.
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INTRODUCTION
In Parkinson’s disease (PD), loss of dopaminergic neurons in the
pars compacta of the substantia nigra (SN) results in a func-
tional impairment of basal ganglia motor circuits, which leads, in
turn, to a characteristic parkinsonian syndrome (Crossman, 1989;
Jenner, 2008) including bradykinesia, resting tremor, rigidity, and
impairment of posture and gait (Jankovic, 2008; Massano and
Bhatia, 2012). L-dihydroxyphenylalanine (L-DOPA) is the most
effective drug for exogenous dopaminergic substitution and can
alleviate most of the manifestations of PD. Long-term L-DOPA
therapy can, however, have disabling complications, including
severe fluctuations of motor function (ON/OFF phenomena)
and abnormal involuntary movements (AIMs; L-DOPA induced
Abbreviations: 6-OHDA, 6-hydroxydopamine; AIMs, abnormal involuntary
movements; DA, dopamine; L-DOPA, L-dihydroxyphenylalanine; OPF, open
field; PD, Parkinson’s disease; TH, tyrosine hydroxylase.
dyskinesia) (Granérus, 1978; Fabbrini et al., 2007). In PD patients,
the improvement or worsening of motor symptoms is measured
with Part III of the UPDRS (Unified Parkinson’s Disease Rating
Scale) in the ON and OFF phases of drug treatment. Typi-
cally, the phase without drug intake (OFF) is characterized by
manifestations such as delayed gait initiation and bradykinesia
(Miyasaki et al., 2002); the phase of drug intake (ON), in which
the L-DOPA level is highest, is characterized by the best clinical
benefit. Dyskinesia usually arises in the ON phase (Guridi et al.,
2012) of chronic L-DOPA treatment and is not seen in the OFF
phase. The risk that a patient will develop dyskinesia depends
on multiple factors including the degree of dopaminergic neu-
rodegeneration (Obeso et al., 2000), the dose and duration of
L-DOPA therapy (Hauser et al., 2006), the age of onset of PD
(Kostic et al., 1991; Schrag, 2006), the presence or absence of
resting tremor (Kipfer et al., 2011), and genetic factors such as
genomic polymorphisms (Linazasoro, 2005). The occurrence of
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dyskinesia in the phase that is, in all other aspects, the patient’s
best motor phase, can severely impair the quality of life (Dodel
et al., 2001). In rodent models of PD, many different tests have
been proposed for the evaluation of motor impairment (Hamers
et al., 2001; Tillerson et al., 2001; Lundblad et al., 2002) after
bilateral or unilateral degeneration of dopamine (DA) cells in the
SN (Cenci et al., 2002), while the severity of dyskinesia is typically
assessed with an analysis of AIMs (Winkler et al., 2002; Cenci and
Lundblad, 2007). In many studies, the efficacy of the unilateral
lesion of the dopaminergic pathway with 6-hydroxydopamine (6-
OHDA) is checked either by spontaneous ipsilateral turning of
the animal to the side of lesion or by the number of ipsilateral and
contralateral rotations induced by amphetamine or apomorphine
injection, respectively (Cenci et al., 1998; Cenci and Lundblad,
2007). Rotation is also a typical ON motor manifestation aris-
ing during L-DOPA treatment. Although the causes of drug-
induced turning behavior have been investigated in multiple
studies (see, e.g., reviews Carta et al., 2006a; Marin et al., 2006),
it remains unclear whether rotation should be considered as a
type of dyskinesia or as an indication of unilateral hypersensitivity
to the 6-OHDA lesion. Behavioral tests such as the cylinder
test, the Rotarod (Dekundy et al., 2007), and the CatWalk test
(Westin et al., 2012) are widely used to score motor deficits in
parkinsonian animals or to quantify motor improvements after
L-DOPA treatment. These tests, however, do not reflect a natural
spontaneous behavior of animals during the motor performance.
In contrast, analysis of the locomotor activity assessed by the
open field test (OPF), is a useful method which accounts of
the spontaneous exploratory behavior of animals and allows to
define a precise time course of the motor activity, for example
in the ON and OFF phases of L-DOPA treatment. In general, it
is unclear how the effect of L-DOPA on the spontaneous motor
activity is related to its effect on dyskinesia. A better understand-
ing of the underlying pathophysiological mechanisms may lead
to a better treatment with L-DOPA in order to avoid L-DOPA
induced dyskinesia. In this study, we tested the hypothesis of a
relationship between dyskinesia and the spontaneous locomotor
activity of parkinsonian animals at several phases of L-DOPA
treatment and with two different doses of L-DOPA. First, we
applied the OPF to assess accurately the motor disturbances
that arise before, during, and after L-DOPA therapy. Then, we
studied the correlation between the locomotor responses and
dyskinesia to determine whether motor activity in the ON and
OFF phases is correlated with the severity of dyskinetic move-
ments.
MATERIALS AND METHODS
ANIMALS
Twenty eight adult female Sprague-Dawley rats, weighing
210–260 g at the beginning of experiment, were randomly housed
in pairs (two rats per cage) from different randomly assigned
groups, under a 24-h cycle with 12 h of light and 12 h of darkness
with free access to food and water. The room temperature, humid-
ity, and air exchange were automatically controlled. The animals
were divided into four groups of seven animals each: three of
them (the PD groups) received a unilateral DA-denervating lesion
by stereotactic injection of 6-OHDA toxin into the right medial
forebrain bundle, as described below; the fourth group (the naive
group) did not receive any surgical treatment. Only one rat from
the PD groups did not display unilateral dopaminergic lesion
and was excluded from data analysis. According to our previous
studies, we did not include a sham-surgery group as control
group, because we have previously demonstrated that the surgery
did not have significant effect on the locomotor performance
and on the nigrostriatal dopaminergic system in the sham group
(Capper-Loup et al., 2013). All animal procedures were approved
by the Animal Research Committee and the Veterinary Office of
the Canton of Bern, Switzerland.
SURGERY
The rats were anesthetized intraperitoneally with a mix-
ture of ketamine (75 mg/kg) and xylazine (10 mg/kg). 6-
hydroxydopamine (10 µg in 4 µl ascorbic acid 0.1%, Capper-
Loup et al., 2005) was injected into the right medial forebrain
bundle at the following coordinates in relation to the bregma:
posterior 4.0 mm, lateral 1.3 mm, and 7.8 mm ventral to the
dura mater, as described by Paxinos and Watson (1986). The 6-
OHDA injection was performed at flow rate of 0.5 µl/min. In
order to verify the efficacy of the unilateral dopaminergic lesion,
all rats were killed at the end of the experiment and the brains
processed for tyrosine hydroxylase (TH) immunohistochemistry
(see below).
EXPERIMENTAL DESIGN AND TREATMENT
The overall PD group (21 rats) was randomly divided into three
subgroups. The PD + L-DOPA 8 mg group and the PD +
L-DOPA 6 mg group (seven rats each) were given intraperitoneal
injections of 8 mg and 6 mg, respectively, of L-DOPA (Sigma-
Aldrich, Buchs, Switzerland) together with 15 mg/kg of benser-
azide (Sigma-Aldrich, Buchs, Switzerland) diluted in NaCl 0.9%,
once a day for 21 days, while the PD + saline group (seven rats)
received saline injections only. The naive group (seven healthy
rats) received the same treatment as the PD + L-DOPA 8 mg
group. The experimenter analyzing the behavior was blinded to
the injection conditions.
SPONTANEOUS LOCOMOTOR TEST
The spontaneous locomotor activity of all animals was tested
in the OPF test during four specific phases (Figure 1): (1) at
baseline before surgical lesioning (“before surgery”); (2) 3 days
before the start of drug treatment (“before treatment”); (3) at day
19 during L-DOPA or saline injection (the “ON phase”); and
(4) at day 22, 1 day after the last drug injection (the “OFF phase”).
A pilot study (data not shown) demonstrated that locomotor
activity was stable already 2 weeks after lesion in PD rats and
we decided to start the behavioral analysis 4 weeks after the
surgery to avoid unnecessary stress during the recovery phase
of the lesioned animals. To evaluate the relationship between
dyskinesia and locomotor activity in the ON phase, we sub-
jected the animals to the OPF test 15 min after the L-DOPA
injection, so that the motor variables could be measured while
dyskinesia was developing. Two animals were put in adjacent
cages and filmed with a video camera. Standard lighting was
maintained during the test. The rats performed the OPF test
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FIGURE 1 | Schematic illustration of experimental design. OPF: open
field test, ( : AIM scoring). The first OPF test was performed before
surgery as individual baseline measure for each rat.
for two periods of 15 min each, separated by a 15 min inter-
val. Videos were analyzed with a computerized tracking system
(Ethovision XT 8.5, Noldus, Wageningen, NL) that followed the
center of the rat’s body. The automatically analyzed locomotor
variables were: “total distance moved”, i.e., the total distance
covered in cm by the animals during the whole 15 min obser-
vation period; “mean velocity”, the mean of all the velocities
calculated for each interval of 0.2 s (time resolution of the
system) during the 15 min observation period; the “maximum
distance moved”, as the maximal distance traveled in cm by the
rats during a single interval of 0.2 s of the 15 min observation
period; and “frequency of rotation”, expressed as the number of
full (360◦) turns taken in the ipsilateral and contralateral direc-
tions relative to the lesion (i.e., clockwise and counterclockwise,
as the lesion was always made on the right side). We follow
the nomenclature of Kalueff et al. (2007) in referring to the
total distance moved, mean velocity, and maximum distance
moved as variables reflecting horizontal motor activity, and to
the frequency of rotation as a variable reflecting turning motor
activity.
RATING OF ABNORMAL INVOLUNTARY MOVEMENT
For quantification of L-DOPA-induced AIMs (see Figure 1), rats
were placed individually in transparent plastic cages and observed
by experimenter during the first minute of every 20-min period in
the 2 h following the injection of L-DOPA or saline. In addition, a
video was taken during the AIMs observation and later analyzed
by an investigator blinded to the online rating previously given
and to the treatment. Both methods revealed similar results. As
described previously (Cenci et al., 1998; Winkler et al., 2002;
Cenci and Lundblad, 2007), dyskinesia was classified as one of
four subtypes, depending on its bodily distribution: (1) axial
AIMs, i.e., lateral flexion of neck and dystonic twisting of trunk
contralaterally, i.e., away from the side of lesion; (2) forelimb
AIMs, i.e., jerky or dystonic movements of the contralateral fore-
limb and/or purposeless grabbing movements of the contralateral
paw; (3) orolingual AIMs, i.e., purposeless jaw movements and
contralateral tongue protrusion; and (4) locomotive AIMs, i.e.,
increased rotation with contralateral side bias and with at least
three paws touching the ground. Each AIM subtype was rated
on a severity scale from 0 to 4 (0 = absent, 1 = occasional, i.e.,
present during less than half of the observation time, 2 = fre-
quent, i.e., present during more than half of the observation
time, 3 = nearly continuous with interruption only by strong
or external sensory stimuli, 4 = continuous and severe). Aside
from this scale, amplitude scores from 0 to 4 were given for
each monitoring period (Cenci et al., 1998; Winkler et al., 2002;
Carta et al., 2006b). The amplitude of axial AIMs was scored
according to the torsional angle of the animal’s neck and upper
trunk with the longitudinal axis of the body; that of forelimb
AIMs, according to the extent of limb displacement and the visible
involvement of proximal muscle groups; that of orolingual AIMs,
according to the extent of involvement of facial, masticatory, and
tongue muscles and the frequency of jaw opening. All animals
were rated on each of 2 days: for each day, a total AIM score
was calculated as the sum of the basic score multiplied by the
amplitude score for each AIM subtype, excluding the locomotive
subtype (Lo) (Carta et al., 2006b; Lundblad et al., 2009). For
each day of AIMs observation, the sum of total AIM scores of
each subtype previously rated, was used to compare the severity
of dyskinesia in the PD + L-DOPA 8 mg and PD + L-DOPA 6 mg
groups across the 21 days of L-DOPA treatment (see in the Section
Results).
TISSUE PREPARATION AND IMMUNOHISTOCHEMISTRY
One day after the last injection of L-DOPA/saline treatment and
after performing the OPF test in the OFF phase, all rats were
intraperitoneally injected with pentobarbital and transcardially
perfused with NaCl 0.9% mixed with heparin, followed by 2%
paraformaldehyde in phosphate-buffered saline at pH 7.4. The
brains were removed, post-fixed for 2 h in the same fixative
solution at room temperature and put overnight in 10% sucrose
at 4◦C. Then the brains were maintained for 3 days in 20% sucrose
at 4◦C, frozen in isopentane solution and finally stored at−70◦C.
Coronal sections of 12-µm thickness were cut on a cryostat
and stored at −70◦C. The brain sections of the PD rats were
processed for TH-immunohistochemistry. Briefly, the sections
were preincubated for 1 h in blocking serum (5% normal horse
serum/0.2% Triton X-100 in phosphate-buffered saline) and were
then incubated overnight at 4◦C with mouse anti-TH diluted
in blocking serum (1:400; Chemicon, Millipore, Temecula, CA,
USA). After washing, the sections were incubated for 1 h at room
temperature in conjugated goat anti-mouse antibody IRDye800
(1:500; Rockland, Gilbertsville, PA, USA). After the final wash, the
sections were allowed to dry before infrared fluorescence scanning
(Odyssey, Li-COR, Lincoln, NE, USA).
MEASURES OF STRIATAL TH DENSITY
For the quantification of striatal TH expression, infrared scan
was analyzed using the public domain Image J program1. The
expression of TH labeling in the caudate-putamen region of the
ipsilateral DA-denervated side was used to check the accuracy of
lesion in two brain sections for each animal, at the rostral level of
the striatum (approximately 2.16 mm anterior from the Bregma),
according to Paxinos and Watson (1986). The mean gray values
were measured for each outlined area and were expressed as the
percentage of the averaged values in the contralateral intact side
1http://imagej.nih.gov/ij
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of the PD + saline group set to 100%. Mean values were calculated
for each animal and used for the statistical analysis.
STATISTICAL ANALYSIS
To analyze the locomotor variables, we used the mean of the
values obtained during the two 15 min observation periods for
each animal, expressed as a percentage of the value for that
animal that was obtained before surgery (i.e., baseline scale set
to 100%). As some of the data were not normally distributed
(Shapiro-Wilk test) and did not show homogeneity of variance
(Levene test), the statistical analysis was performed with non-
parametric tests exclusively. Friedman’s χ2 test was performed to
evaluate a general effect of the distinct treatment phases (before,
during (ON) and after (OFF) drug injection) within groups.
Then, the post hoc Wilcoxon signed-rank test (Z) was carried
out for pairwise comparisons. The Kruskall-Wallis test (H) was
performed to assess the general effect of treatment phases across
groups. The post hoc Mann-Whitney test (U) was performed
for groupwise comparisons. The AIM scores were normally dis-
tributed with homogeneous variance, and we therefore used
ANOVA for repeated measures (repeated factor: time in days) to
assess the effect of “time” on “treatment” (two levels: L-DOPA
8 mg, L-DOPA 6 mg) and their interaction. A post hoc paired T-
test was used to evaluate the difference between the treatment days
within each group given 8 mg/kg and 6 mg/kg of L-DOPA.
Finally, the correlation between the measured motor variables and
the AIM scores was analyzed with Spearman’s non-parametric
correlation test.
For the analysis of the striatal TH expression, one-way ANOVA
was performed to assess the effect of lesion in the DA-denervated
side across groups. Then paired T-test was used to evaluate the
difference between denervated and intact side within each group
(significance level was corrected for multiple comparisons). All
data were analyzed for a total number of 27 animals, after exclu-
sion of one rat from the PD + saline group because of failure of
dopaminergic lesion with 6-OHDA toxin as demonstrated by TH
immunohistochemistry (see Section Results). The data are given
as mean ± SEM. All analyses were performed with SPSS software
(version 15.0, SPSS Inc., Chicago IL, USA). Level of significance
was set to p< 0.05.
RESULTS
HORIZONTAL MOTOR VARIABLES
Total distance moved and mean velocity
The analysis of total distance moved and mean velocity revealed
different motor responses of the groups across treatment phases.
The results obtained for both variables were comparable without
any significant difference between them (Figure 2A shows only
the data for the total distance moved). All animals lesioned
with the 6-OHDA toxin (the overall PD group) had reduced
locomotor activity for total distance traveled (PD + L-DOPA
8 mg: 68.2% ± 4.3%; PD + L-DOPA 6 mg: 72.4% ± 8.7%;
PD + saline: 66.2% ± 9.0%) and mean velocity (PD + L-DOPA
8 mg: 67.94% ± 4.3%; PD + L-DOPA 6 mg: 72.3% ± 8.7%;
PD + saline: 66.1% ± 9.0%) in the “before treatment” phase
compared to the “before surgery” phase (with the baseline value
set to 100%, as mentioned above). The observed reduction in
total distance moved and in mean velocity in each subgroup
of the overall PD group differed significantly from that seen in
the naive group, as expected (PD + L-DOPA 8 mg: U = 1.000,
P < 0.01; PD + L-DOPA 6 mg: U = 6.000, P < 0.05; PD + saline:
U = 4.000, P < 0.05). For each of these two motor variables, the
observed values varied significantly across treatment phases in the
PD + L-DOPA 8 mg group (χ2(2) = 12.286, P < 0.01) and in
the PD + L-DOPA 6 mg group (χ2(2) = 14, P < 0.001). Both
groups had more locomotor activity in the ON phase than before
treatment and OFF phase (PD + L-DOPA 8 mg: Z = −2.366,
P< 0.05; PD + L-DOPA 6: Z =−2.366, P< 0.05 vs. both phases),
as well as significantly less movement in the OFF phase compared
to before treatment (PD + L-DOPA 8 mg: Z = −2.197, P < 0.05;
PD + L-DOPA 6 mg: Z = −2.366, P < 0.05). The increase of
the motor response in the ON phase was significantly different
in the PD + L-DOPA 8 mg and 6 mg groups compared to the
PD + saline group (U = 0.000, P < 0.01; U = 5.000, P < 0.05,
respectively). In the OFF phase, the reduction of motor activity
in the PD groups still differed significantly from that in the naive
group (PD + L-DOPA 8 mg: U = 0.000, P < 0.01; PD + L-DOPA
6 mg: U = 0.000, P < 0.01; PD + saline: U = 0.000, P < 0.01).
Aside from this quantitative motor analysis, we also qualitatively
observed that the animals tended to become excited, sniff, and
eat immediately after each L-DOPA injection, in conjunction
with locomotor hyperactivity. In the OFF phase, in contrast, they
tended to rest in one corner of the cage without showing any other
interest in conjunction with their reduced locomotor activity.
The motor responses in the PD + saline group did not differ
significantly across treatment phases although a small decrease
of total distance moved and mean velocity was seen in the OFF
phase (total distance moved: 59.74% ± 2.69 (Figure 2A); mean
velocity: 59.73% ± 2.67%) compared to the ON phase (total
distance moved 79.5% ± 5.8%; mean velocity 79.6% ± 5.8%).
All values still remained below the baseline level before surgery
(100%). The naive group showed a slight but significant decrease
of locomotor activity in the ON phase compared to the before
treatment and OFF phases (Z = −2.366, P < 0.05; Z= −2.197,
P < 0.05, respectively).
Maximum distance moved
The experimental groups differed less clearly with respect to
the maximum distance moved variable than in the other two
variables discussed above (Figure 2B). A significant difference
of maximum distance moved across treatment phases was found
in the PD + L-DOPA 8 mg group (χ2(2) = 8, P < 0.05) and
the PD + L-DOPA 6 mg group (χ2(2) = 10.571, P < 0.01).
These two groups had higher values in the ON than in the OFF
phase (Z = −2.366, P < 0.05 for both groups; Figure 2B). There
was no significant difference of maximum distance moved across
treatment phases in the PD + saline group or in the naive group.
TURNING MOTOR VARIABLE
Ipsilateral and contralateral frequency of rotation
To assess turning behavior, the number of full turns (360◦) toward
and away from the side of the lesion was automatically counted.
The frequency of rotation varied across treatment phases in all
experimental groups (Figures 3A,B,C). For contralateral rotation,
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FIGURE 2 | Horizontal motor activity. (A,B) Mean of percentage values
( ± S.E.M.) of the total distance moved and maximum distance moved in
the several treatment phases referring to individual values (set to 100%)
recorded before surgery. (A) The PD + L-DOPA 8 mg and PD + L-DOPA
6 mg groups had more intense locomotor activity in the ON phase than in
the other treatment phases (*p < 0.05 vs. before treatment and OFF
phase). Both PD + L-DOPA groups had a less intense motor activity in the
OFF phase than in the phase before drug treatment (◦p < 0.05 vs. before
treatment). The naive group had a higher distance traveled in the phase
before treatment and in OFF phase (+p < 0.05 vs. the ON phase).
Differences between subjects were also seen within each treatment phase
(before treatment: §p < 0.05 vs. the naive group; ON phase: §p < 0.05 vs.
PD + saline group; OFF phase: §p < 0.05 vs. naive group). (B) The PD +
L-DOPA 8 mg and PD + L-DOPA 6 mg groups had higher values of
maximum distance traveled in the ON phase than the OFF phase
(*p < 0.05 vs. the OFF phase).
there was a significant difference across treatment phases in the
PD + L-DOPA 8 mg group (χ2(2) = 11.185, P < 0.01) and
the PD + L-DOPA 6 mg group (χ2(2)= 12.286, P < 0.01).
Both groups had a higher frequency of ipsilateral rotation in
the before treatment and OFF phases (PD + L-DOPA 8 mg:
Z = −2.366, P < 0.05; PD + L-DOPA 6 mg: Z = −2.201,
P < 0.05 vs. contralateral rotation, Figures 3A,C); while con-
tralateral turns were more frequent in the ON phase (PD +
L-DOPA 8 mg: Z = −2.366, P < 0.05; PD + L-DOPA 6 mg:
Z = −2.366, P < 0.05 vs. ipsilateral rotation, Figure 3B). In the
PD + saline group, ipsilateral turns were more common in all
treatment phases (Z =−2.201, P< 0.05 vs. contralateral rotation,
Figures 3A,B,C).
COMPARISON OF AIM SCORE IN PD GROUPS
The AIMs occurred only in the PD groups that received daily
L-DOPA injections (8 mg and 6 mg), while no dyskinesia was
seen in the naive group or in the PD group that was treated only
with saline. The severity of AIMs was significantly different across
treatment days (effect of time: F(4.805, 57.662) = 8.463, p < 0.001;
Figure 4). Bodily AIMs (axial, limbic, and orolingual subtypes)
were more severe from the eighth day of L-DOPA treatment
in both of the PD + L-DOPA groups (PD + L-DOPA 8 mg:
t(6) = −4.384; p < 0.01 vs. the first day and t(6) = −4.158;
p < 0.01 vs. the second day; PD + L-DOPA 6 mg: t(6) = −7.298;
p < 0.001 vs. the first day and t(6) = −3.825; p < 0.01 vs. the
second day; Figure 4). After 1 week of daily L-DOPA injections
(from the eighth day) the severity of dyskinetic movements
reached a plateau value that was maintained similar until the end
of treatment days (p > 0.05 vs. the 21st day in both PD + L-DOPA
groups). Finally, the PD + L-DOPA 8 mg group and the PD +
L-DOPA 6 mg group had comparable AIM scores between them
and no significant effect time ∗ treatment was found.
CORRELATION BETWEEN MOTOR VARIABLES AND AIM SCORES
As it was difficult to rate AIMs accurately during the OPF test, we
decided to use for correlation analysis the AIMs rated 1 day before
the OPF test in a similar ON phase (on the 18th day of L-DOPA
treatment, see Figure 1). No correlation was found between the
bodily AIM scores and the locomotor variables recorded in ON
and OFF phase of L-DOPA treatment (data not shown). However,
there was a significant positive correlation between the Lo and the
total distance moved (r = 0.786, p < 0.05; Figure 5), only in the
PD + L-DOPA 8 mg group during the ON phase.
TH-IMMUNOREACTIVITY
As expected, all PD rats showed a severe and significant reduction
of TH expression in the 6-OHDA injected side compared to the
intact side, confirming the accuracy of the DA lesion (PD +
L-DOPA 8 mg: t(6) = 45.288 p < 0.001; PD + L-DOPA 6 mg:
t(6) = 60.612 p < 0.001; PD + saline t(5) = 30.902 p < 0.001;
Figures 6A,B). Only one rat of the PD + saline group did not
present loss of TH fibers in the lesion side and was excluded
from data analysis. All PD groups showed a similar loss of
TH immunoreactivity without any significant differences across
groups.
DISCUSSION
Our findings demonstrate that there is no relationship between
the severity of dyskinesia and the spontaneous locomotor activity
in parkinsonian animals during the ON and OFF phases of
L-DOPA treatment. In particular, the severity of bradykinesia in
the OFF phase was not correlated with the severity of dyskinesia.
Only the pathological rotation induced by the higher dose of
L-DOPA was found to be correlated with a higher motor response
in the ON phase of L-DOPA treatment. Our behavioral results
suggest that two different neural mechanisms are involved in
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FIGURE 3 | Turning motor activity. (A–C) Mean of values (±S.E.M.) of the
frequency of rotation in the different treatment phases, expressed as
percentages of the individual baseline values (set to 100%) that were
(Continued )
FIGURE 3 | Continued
recorded before surgery. (A,C) The PD + L-DOPA groups showed more
frequent ipsilateral rotation before drug treatment and in the OFF phase
(*p < 0.05 vs. the contralateral rotation). (B) More frequent contralateral
rotation was seen in the ON phase (*p < 0.05 vs. ipsilateral rotation). (A–C)
In contrast, the PD + saline group manifested ipsilateral rotation in all three
treatment phases (◦p < 0.05 vs. contralateral rotations).
FIGURE 4 | AIM scores. Comparison of the bodily (axial, limbic and
orolingual) AIM scores developing during chronic treatment at two different
L-DOPA dosages. For each day, a total AIM score was calculated as the sum
of the basic score multiplied by the amplitude score for each AIM subtype,
excluding the locomotive subtype (Lo). The graph expresses the mean of
the total AIM scores (±S.E.M.) for all animals during each day of treatment.
The severity of the bodily AIMs increased after 1 week (from the eighth day)
of daily L-DOPA injections in both treated groups (PD + L-DOPA 8 mg:
*p < 0.01 and PD + L-DOPA 6 mg: ◦p < 0.001 vs. the first and second day).
FIGURE 5 | Spearman’s correlation. Scatter plots for locomotive AIM
subtype, rated on the18th day of L-DOPA treatment, plotted against the
total distance moved (expressed in % values) during the ON phase. The
graphs represent individual data points for all animals of the PD groups
receiving L-DOPA treatment at doses of 8 mg and 6 mg. A significant
positive correlation was found only in the PD + L-DOPA 8 mg group.
(Spearman’s coefficient: r = 0.786, p < 0.05).
the development of dyskinesia and the control of motor per-
formance. Although many studies have already investigated the
motor changes and the dyskinesia in parkinsonian animal model,
for our knowledge this is the first study that assesses in parallel,
the spontaneous locomotor responses of parkinsonian animals at
specific phases of L-DOPA treatment and correlates these motor
responses with the severity of dyskinetic movements.
CORRELATION OF ROTATION MOVEMENTS INDUCED BY L-DOPA AND
MOTOR PARAMETERS
In parkinsonian rats treated with L-DOPA, the locomotor activity
and the movement velocity were higher during the ON phase of
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FIGURE 6 | TH density. (A) The graph represents the percentage
values of TH density (±S.E.M.) in both hemispheres referring to the
averaged values in the intact contralateral side of PD + saline group
(set at 100%). All PD rats had a significant reduction of the TH
density in the DA-denervated side compared to the contralateral side
within each group (*** p < 0.001 vs. contralateral side).
(B) Representative image of DA denervation in the right side of the
striatum. Scale bar = 3 mm.
L-DOPA treatment than before and after treatment, as expected.
We used two low L-DOPA doses (6 and 8 mg/kg respectively) that
are comparable to the doses used in humans and that are known
to induce AIMs in parkinsonian animals (Lundblad et al., 2002;
Winkler et al., 2002). Despite the small difference between the
two dosages, they clearly differed in their propensity to induce
contralateral rotation with increased locomotor activity in the ON
phase. The rats treated with 8 mg of L-DOPA had a more intense
motor response and more frequent contralateral turns than those
treated with 6 mg, although the degree of DA denervation did
not differ across the two PD + L-DOPA groups. Nonetheless, the
severity and progression of dyskinesia were similar in the two
groups.
To assess whether the increased locomotor behavior was linked
with, or perhaps due to, the rotational movements (locomo-
tive AIM scores) or, alternatively, with classic bodily dyskinesia
(body AIM), which closely resembles the choreatic dyskinesia
seen in humans, we analyzed the relationship between the AIM
scores and the locomotor variables of the parkinsonian rats
treated with L-DOPA (at higher and lower doses) in the ON
and OFF phases. Only the rotational movements measured with
the AIM score and induced by L-DOPA at the 8 mg dose were
correlated with more intense locomotor activity during the ON
phase. Individual variability in the motor responses to higher
dose of L-DOPA in the PD + L-DOPA 8 mg group, likely
explains the correlation observed only in this group, between
the rotational movements and the values for the distance trav-
eled. Our results strongly confirm that slightly different L-DOPA
dosages can have different effects on spontaneous motor per-
formances without influencing the severity of dyskinesia. As
previously suggested (Lundblad et al., 2002), pathological con-
tralateral rotation should not be regarded as a valid measure
of dyskinesia (Lundblad et al., 2002), but rather as a manifes-
tation of the hypersensitivity of the lesioned side to L-DOPA
treatment (Ungerstedt, 1976; Tolwani et al., 1999). Our findings
are consistent with these previous findings and suggest that the
neural mechanisms leading to dyskinesia differ from those that
mediate spontaneous motor responses, with different dose-effect
relationships. A previous study on rats that were made parkin-
sonian with 6-OHDA lesioning did not reveal any significant
correlation between amphetamine-induced rotation and motor
behavior (Metz and Whishaw, 2002). Further studies are needed
to improve our understanding of the pathways responsible for the
motor and dyskinetic manifestations. Conceivably, the direct and
indirect pathways, which are differently modulated by chronic
L-DOPA treatment, might be involved in the control of locomotor
activity and in the development of the involuntary movements,
respectively.
MOTOR AND NON-MOTOR RESPONSES IN PARKINSONIAN RATS
AFTER L-DOPA WITHDRAWAL
Interestingly, in both groups of parkinsonian rats treated with
L-DOPA, locomotor activity was lower after L-DOPA was discon-
tinued (the OFF phase) than before starting L-DOPA treatment.
This state of hypomobility resembles the OFF motor state of
parkinsonian patients after L-DOPA is stopped and the therapeu-
tic effect of the drug wears off. We hypothesize that the decreased
motor performance in the OFF phase, only seen in the two PD
groups given L-DOPA, might be due to a combined motor and
non-motor effect of L-DOPA withdrawal, and not just to the
freezing of gait that often reflects the OFF condition (Jankovic,
2005; Devos et al., 2010). In this study, we qualitatively observed
an overall “excited” behavioral state a few minutes after each
L-DOPA injection in the ON phase and, in contrast, a quiet
behavioral state in the OFF phase. In a possibly related finding,
studies of non-motor manifestations in patients with PD have
shown that chronic L-DOPA treatment may promote the devel-
opment, not just of motor fluctuations, but of mood fluctuations
as well (Maricle et al., 1995; Kulisevsky et al., 2007). Significant
mood changes have been found to be associated with ON/OFF
phenomena in patients with PD (Nissenbaum et al., 1987; Menza
et al., 1990). Fluctuating euphoria (76%) and hyperactivity (94%)
were found in the ON motor state, while anxiety was more
common in the OFF motor state (88%) (Witjas et al., 2002).
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The observation and analysis of spontaneous animal behavior,
as in our study, may be a useful tool for the assessment of
both motor and non-motor effects of L-DOPA treatment but it
cannot differentiate between both. Specific tests for anxiety and
for a depressive state would be needed for a better and specific
assessment of non-motor manifestations.
NO MOTOR BEHAVIORAL CHANGES IN THE NAIVE GROUP
In this study, we also analyzed the effect of L-DOPA in healthy
rats. Locomotor activity was similar before and after L-DOPA
treatment while in the ON phase, a reduction of the motor state
might be due to the side effects of chronic L-DOPA treatment,
such as nausea, that frequently also develop in parkinsonian
patients. In accordance with observations on healthy subjects
(Newman et al., 1985) or subjects with essential tremor erro-
neously treated with L-DOPA, our findings confirm that thera-
peutic doses of L-DOPA have no effect on the locomotor per-
formance or the dyskinesia development in healthy rats. This
confirms that the extent of striatal dopaminergic denervation
is an important determinant of the pharmacological activity of
L-DOPA and the development of its secondary effects, including
dyskinesia (Cenci and Lundblad, 2006; Putterman et al., 2007).
CONCLUSION
This study shows that the severity of dyskinesia is not correlated
with the locomotor activity in the ON and OFF phases of L-DOPA
treatment; rather, only the rotational movements induced by
higher dose of L-DOPA are correlated with higher locomotor
activity in the ON phase. In addition, a combined motor and non-
motor L-DOPA withdrawal effect could explain a lower motor
performance in the OFF phase of L-DOPA treatment compared
to the phase before starting the L-DOPA treatment. The analysis
of spontaneous animal locomotor activity with the OPF test is a
useful methodological approach for analyzing accurately behav-
ioral responses that resemble the motor disturbances of human
patients with PD at several phases of L-DOPA treatment.
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